For Life Science Founders
Physician-led risk assessment across regulatory, clinical, IP, and commercial — so you walk into every investor meeting knowing the gaps before they do.
Know your regulatory and clinical risk profile before investors ask. Identify gaps early so you can address them on your timeline, not theirs.
Your technology is strong. Our job is to make sure every investor, regulator, and partner sees the full picture — and says yes.
Your Assessment Team
Led by Dr. Arvind Ravinutala (MD, practicing physician) and Aswini Ravinutala (BME, 8+ years medical device engineering, ex-Axonics/Boston Scientific). Meet the full team →
Clarity
Your Vantage Score distills complex clinical-technical risk into a single confidence rating.
Your Vantage Score
A single number that synthesizes clinical viability, regulatory clarity, manufacturing feasibility, reimbursement pathway, IP strength, team readiness, market timing, and investor confidence. This is what VCs actually evaluate — all of it distilled.
70+: GREEN - Investment Ready
Your clinical-technical-commercial position is strong. Risks are identified and addressable. Ready to go to market or fundraise.
50-69: YELLOW - Addressable Risk
You have material gaps. They're not fatal, but they need fixing. Your report prioritizes them. Fix before major fundraise rounds.
Below 50: RED - Critical Issues
Major risks that investors will immediately flag. Your report shows exactly what needs to change and realistic timelines.
After your assessment, you have clarity and a roadmap. Here's how founders typically proceed.
You submit materials through our secure portal (pitch deck, regulatory strategy, IP documentation, clinical data). Our team reviews your submission and confirms scope and timeline. We ask clarifying questions if needed.
Your physician assesses clinical adoption barriers, evidence gaps, reimbursement pathways, and regulatory strategy. Your engineer assesses manufacturing feasibility, IP strength, technical regulatory requirements, and go-to-market timing. They work in parallel, reconvene to synthesize findings.
You receive a comprehensive report with your risk profile, executive summary, and prioritized action plan. Then a 30-minute call with your assessors to discuss findings, challenge recommendations, and align on next steps. Many founders bring their board or co-founder to this call.
If critical gaps need modeling: Scenario Planning ($2,500/scenario). If you want ongoing intelligence: Regulatory Tracking ($1,500/month). If you're preparing Series B: Full Deep-Dive Assessment ($15,000+). Most founders use at least one follow-on service in the next 6 months.
Investors scrutinize clinical AND regulatory strategy. You're expert in one. We cover both — plus 18 other risk categories — in 48 hours.
Success Pathway
Your Vantage assessment becomes a proof point in investor diligence.
You have your risk profile, narrative findings, and action plan. Your score tells you exactly where you stand.
Red flags identified? Scenario model the fix. Not urgent? Continue fundraising with your action plan in hand.
You share your Vantage assessment in the data room. VCs see that you've already completed independent clinical-technical diligence. Accelerates their process.
Vantage assessment becomes a data point in investor confidence. You're not just pitching — you're proving you've already solved the due diligence puzzle.
What You'll Receive
Every assessment includes these components in your deliverable.
Comprehensive proprietary assessment producing a calibrated 0-100 Vantage Score. GREEN means investment-ready. YELLOW means addressable gaps. RED means critical issues requiring immediate attention. Your score includes confidence indicators showing where data gaps may affect conclusions.
What you're doing well. Where your biggest risks sit. Why they matter for investors. How to talk about them in investor meetings. This is the section you share with VCs who ask about clinical and regulatory strategy.
Top 5-7 remediations ranked by impact and timeline. Each item includes owner, deadline, success criteria, and estimated cost/resource impact. This becomes your roadmap for the next 12-18 months.
For each assessment domain, detailed findings, specific recommendations, and evidence from regulatory databases, competitive analysis, and clinical literature. This is the "why" behind your score.
Direct conversation with your physician and engineer assessors. Walk through the findings, ask follow-up questions, pressure-test the recommendations, and get clarity on next steps. Many founders use this call to plan their board conversations.
Strategic Guidance
How 510(k) classification drives your timeline. Common delays and how to avoid them.
What stops physicians from using your technology. How to assess workflow integration early.
Beyond pitch decks. What due diligence questions VCs always ask about regulatory and clinical risk.
What founders ask us first
The most common questions from inbound founder calls — and how we answer them before any check is cut.
Q · Predicate strategy
"VCs keep asking about my 510(k) predicate. What's the cheapest way to know if it actually holds up?"
A $2,500 Quick Score tests the predicate against FDA classification history, recent clearance patterns in your subclass, and the 3 most likely reviewer objections — delivered in 24 hours. If it holds, you have a defensible answer for the next IC. If it doesn't, you've spent $2,500 instead of $200K finding out the hard way.
Q · Reimbursement reality
"We're pre-revenue. How do I figure out what payers will actually pay before I commit to a price?"
The Full Score ($7,500) maps your candidate codes against the most recent CMS rate schedule, comparable LCDs, and 3 named precedent payer decisions — with the gaps that would block a coverage determination called out explicitly. It's the same exercise a hospital P&T committee runs before formulary inclusion.
Q · Adoption risk
"Our pilot data looks great. Why do investors still treat adoption as our biggest risk?"
Because pilot environments rarely reflect the workflow constraints of staff who'd actually use the device daily. Our adoption read scores against documented integration patterns, comparable launches in your subclass, and the specific clinician-workflow risks the assessment surfaces — so you can pre-empt the question before it's asked.
Next Steps
Model regulatory or commercial scenarios. Best/base/worst case analysis with timeline and cost impacts.
Ongoing monitoring of FDA guidance, competitor filings, and reimbursement updates in your space.
Across All Modalities
Medical Devices & Sensors
Surgical instruments, diagnostic devices, wearables, monitoring equipment. Assessment covers 510(k) strategy, clinical workflow integration, and manufacturing feasibility.
Drugs & Biologics
Small molecules, monoclonal antibodies, cell and gene therapy. Assessment covers IND pathway, clinical trial design, manufacturing scale-up, and reimbursement strategy.
Diagnostics & Digital Health
In vitro diagnostics, LDTs, software-as-medical-device, clinical decision support. Assessment covers CLIA/CDRH pathways, algorithm validation, and healthcare system integration.
Combination Products
Device + drug, device + software, software + pharma. Assessment determines lead center and integrated regulatory pathway complexity.
Efficiency & Expertise
You could hire consultants, interview payers, and do your own regulatory research. But founders tell us this comparison speaks for itself.
Your approach
DIY Research
Vantage approach
Integrated Assessment
Typical outcome
Time Saved & Value
10 technical risks investors will find. Get ahead of them.
Companies that skip clinical-technical due diligence face an average 3.2x higher write-down rate.
Start with a 48-hour assessment. Then upgrade to a full diagnostic if needed.
Email arvind@vantagebiomed.com directly
Founder Score gives you a data-driven risk profile across all critical domains in 48 hours. Most founders then upgrade to the Full Assessment for deeper insights before fundraising.
†1-4 Vantage proprietary findings based on retrospective analysis of documented life science outcomes. †5 Proximo Medical; MDDI Online. †6 MedDevice Online.